Ozempic and Wegovy: The pros and cons, explained
Photo:
ROBERTO PFEIL / AFP
Earlier this week semaglutide drugs Ozempic and Wegovy
were made available for prescription in New Zealand
.
Semaglutide originally arrived on the market in the US in 2017 as a diabetes medication, but has quickly been tied to
extreme weight loss
.
Wegovy can be prescribed to people over the age of 12, but many of the 65 percent of New Zealanders who are overweight or obese will have trouble affording it, with an estimated price of $500 a month.
The drugs have transformed our ability to manage obesity and type 2 diabetes, and have shown potential for a wide range of conditions such as Alzheimer's, addiction and depression.
But there are clouds to go along with the silver linings - such as potential vision loss.
"This condition, it occurs when there's insufficient blood flow to the nerves connecting the eye to the brain, and this leads to damage," US-based health reporter for
New Scientist
, Grace Wade, told RNZ's
Sunday Morning
. The specific condition was non-arteritic anterior ischemic optic neuropathy.
"That can cause this sudden and permanent vision loss, usually in just one eye. Now, I should be clear this isn't total vision loss, at least usually - it's more like cloudiness, stuff like that."
People using semaglutides to treat diabetes were 4.3 times more likely to develop this condition, and those using it for weight loss 7.6 times, as people using other types of diabetes medications, a 2024 study found (Wade wrote about it in
New Scientist
here
).
The drugs work by suppressing appetite, which typically leads to weight loss as people consume fewer calories. But the weight lost was not always beneficial, Wade said.
"It leads the body to break down fat, muscle and actually even bone for nutrients, and that's why… some research has found that upwards of 40 percent of the weight loss seen with these medications is due to loss of muscle mass… that makes it really important that people prioritise exercise when taking these drugs because if you don't use your muscle, you're more likely to lose it."
Getting into the exercise habit was also important since one day, most people on Ozempic or Wegovy will stop taking it - putting themselves at risk of putting the weight back on if they were not regularly moving.
Then there is 'Ozempic face'.
"I don't think this is a clinical term yet, but it's something that's popped up a lot in social media," Wade said.
"People who are taking these medications start developing... a sunken or hollowed out appearance, which can exacerbate fine lines and wrinkles, make their skin look a little more saggy.
"It isn't clear exactly how common this is… but it probably has to do with just weight loss, right? If you're losing weight, as much as some people would want to target their weight loss to certain areas of their body, we can't really do that. So, you know, any sort of overall weight loss is also gonna cause a loss of fat in your face."
There were also side effects for some, including constantly needing to go to the toilet, feeling bloated, belching, constipation, heartburn, fever, upset stomach - the list,
collected here by the Mayo Clinic, goes on
.
And nearly half of people who try it make it through a three-month course, one study found.
Wade also mentioned a lot of people taking semaglutide for diabetes or Alzheimer's prevention might be older and "frail", so not able to lose weight.
"Drug developers are actually working to develop new drugs that have similar effects as these weight loss medications, but without the weight loss."
One unexpected benefit of semaglutide was its apparent effect on not just calorie consumption, but use of addictive substances, such as alcohol and nicotine.
"We aren't exactly sure why that is, but it appears to be with how these medications affect brain activity.
"So these drugs curb cravings for alcohol similar to how they curb cravings for food, right? And that probably has to do with their impact on brain regions involved in reward processing and craving…
"A study of more than half-a-million people with a history of opioid use disorders showed that those who took Ozempic or similar [medications] had significantly lower rates of opioid overdose than those who didn't.
Grace Wade.
Photo:
New Scientist
"Other studies have shown similar effects in people with cannabis use disorder, cigarette smokers and alcoholism."
Scientists did not expect this effect, calling it an "unintended consequence".
The drugs have also shown promise in reducing heart attacks and strokes, improving fertility, treating pain, improving mental health, lower the risk of kidney failure and slowing cognitive decline.
"I've never encountered a group of drugs like this," Wade said. "That's what makes these drugs so remarkable, because most medications can only treat one or two conditions, right?"
She said it was likely that weight loss was playing a role - as it frequently does in health - but "it doesn't seem to be the only [reason]".
But there is still a lot of research to be done, she said, before we all start taking it.
"Let's unravel how they can treat all of these conditions before we jump the gun and start suggesting we, you know, maybe put it in everyone's water or something."
Sign up for Ngā Pitopito Kōrero, a daily newsletter
curated by our editors and delivered straight to your inbox every weekday.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

RNZ News
3 hours ago
- RNZ News
Health NZ board re-established by government
Health New Zealand commissioner Lester Levy will chair the new governance board for the next year. Photo: RNZ / Nick Monro The government is re-establishing the Health New Zealand governance board, putting current commissioner Lester Levy in charge. The board was axed a year ago, when the government said it had serious concerns about oversight and a budget blow-out. Levy was then brought in to lead the agency, saying his priorities were reducing wait times and improving productivity . Health Minister Simeon Brown said under Levy's leadership as commissioner, Health New Zealand had delivered a strong financial plan, and a clear health delivery plan was now in place. "He is refocusing the organisation on patients and driving progress on the government's health targets, which are seeing waitlists reduced," Brown said. Brown said Levy would chair the new board for a 12 month term to ensure continuity of leadership. He said he would begin a nomination process later this year for a permanent chair to take effect from July next year. Other key appointments announced by the minister: Sign up for Ngā Pitopito Kōrero, a daily newsletter curated by our editors and delivered straight to your inbox every weekday.

RNZ News
5 hours ago
- RNZ News
Weight loss drug Wegovy: The pros and cons, explained
This story has been corrected as an earlier version said Wegovy AND Ozempic had been made available on prescription for weight loss in New Zealand but it is only Wegovy. Wegovy is injected daily and promotes a feeling of fullness while silencing "food noise." Photo: LISE ASERUD Earlier this week semaglutide drug Wegovy was made available for prescription in New Zealand . Semaglutide originally arrived on the market in the US in 2017 as a diabetes medication, but has quickly been tied to extreme weight loss . Wegovy can be prescribed to people over the age of 12, but many of the 65 percent of New Zealanders who are overweight or obese will have trouble affording it, with an estimated price of $500 a month. The drug has transformed our ability to manage obesity and type 2 diabetes, and has shown potential for a wide range of conditions such as Alzheimer's, addiction and depression. But there are clouds to go along with the silver linings - such as potential vision loss. "This condition, it occurs when there's insufficient blood flow to the nerves connecting the eye to the brain, and this leads to damage," US-based health reporter for New Scientist , Grace Wade, told RNZ's Sunday Morning . The specific condition was non-arteritic anterior ischemic optic neuropathy. "That can cause this sudden and permanent vision loss, usually in just one eye. Now, I should be clear this isn't total vision loss, at least usually - it's more like cloudiness, stuff like that." People using semaglutides to treat diabetes were 4.3 times more likely to develop this condition, and those using it for weight loss 7.6 times, as people using other types of diabetes medications, a 2024 study found (Wade wrote about it in New Scientist here ). Novo Nordisk, the maker of Wegovy, said in a statement, patient safety was the top priority and all reports of adverse events were taken seriously. "Semaglutide has been studied in robust clinical development programs with more than 52,000 semaglutide exposed patients and exposure from post-marketing use of over 33 million patient years." It said it was recommended to update patient leaflets for Wegovy and Ozempic on June 6 to include the condition under its special warnings and precautions for use and as an adverse drug reaction with a frequency of "very rare, meaning it may effect up to 1 in 10,000 people taking semaglutide". It said based on the totality of evidence it concluded the data did not suggest a reasonable possibility of a casual relationship between the condition and semaglutide and "the benefit-risk profile of semaglutide remains favourable". "We work closely with authorities and regulatory bodies worldwide to continuously monitor the safety profile of our products." The drug worked by suppressing appetite, which typically leads to weight loss as people consume fewer calories. But the weight lost was not always beneficial, Wade said. "It leads the body to break down fat, muscle and actually even bone for nutrients, and that's why… some research has found that upwards of 40 percent of the weight loss seen with these medications is due to loss of muscle mass… that makes it really important that people prioritise exercise when taking these drugs because if you don't use your muscle, you're more likely to lose it." Getting into the exercise habit was also important since one day, most people on Wegovy will stop taking it - putting themselves at risk of putting the weight back on if they were not regularly moving. Then there is 'Ozempic face'. "I don't think this is a clinical term yet, but it's something that's popped up a lot in social media," Wade said. "People who are taking these medications start developing... a sunken or hollowed out appearance, which can exacerbate fine lines and wrinkles, make their skin look a little more saggy. "It isn't clear exactly how common this is… but it probably has to do with just weight loss, right? If you're losing weight, as much as some people would want to target their weight loss to certain areas of their body, we can't really do that. So, you know, any sort of overall weight loss is also gonna cause a loss of fat in your face." There were also side effects for some, including constantly needing to go to the toilet, feeling bloated, belching, constipation, heartburn, fever, upset stomach - the list, collected here by the Mayo Clinic, goes on . And nearly half of people who try it make it through a three-month course, one study found. Wade also mentioned a lot of people taking semaglutide for diabetes or Alzheimer's prevention might be older and "frail", so not able to lose weight. "Drug developers are actually working to develop new drugs that have similar effects as these weight loss medications, but without the weight loss." One unexpected benefit of semaglutide was its apparent effect on not just calorie consumption, but use of addictive substances, such as alcohol and nicotine. "We aren't exactly sure why that is, but it appears to be with how these medications affect brain activity. "So these drugs curb cravings for alcohol similar to how they curb cravings for food, right? And that probably has to do with their impact on brain regions involved in reward processing and craving… "A study of more than half-a-million people with a history of opioid use disorders showed that those who took Ozempic or similar [medications] had significantly lower rates of opioid overdose than those who didn't. Grace Wade. Photo: New Scientist "Other studies have shown similar effects in people with cannabis use disorder, cigarette smokers and alcoholism." Scientists did not expect this effect, calling it an "unintended consequence". The drugs have also shown promise in reducing heart attacks and strokes, improving fertility, treating pain, improving mental health, lower the risk of kidney failure and slowing cognitive decline. "I've never encountered a group of drugs like this," Wade said. "That's what makes these drugs so remarkable, because most medications can only treat one or two conditions, right?" She said it was likely that weight loss was playing a role - as it frequently does in health - but "it doesn't seem to be the only [reason]". But there is still a lot of research to be done, she said, before we all start taking it. "Let's unravel how they can treat all of these conditions before we jump the gun and start suggesting we, you know, maybe put it in everyone's water or something." Sign up for Ngā Pitopito Kōrero, a daily newsletter curated by our editors and delivered straight to your inbox every weekday.

RNZ News
6 hours ago
- RNZ News
As it happened: First public hearings into New Zealand's Covid-19 response begin
Heart of the City chief executive Viv Beck, right, and employment relations and safety manager Paul Jarvie. Photo: The first public hearings into New Zealand's Covid response get under way on Monday - with a focus on lockdowns and vaccines. The Royal Commission of Inquiry into Covid-19 is looking into the government's response to the pandemic and its effects. It is the first time submissions will be heard publicly, with the sessions livestreamed. You can follow updates from today in our live blog above. This week's hearings particularly concentrate on the impact of the extended lockdown in Auckland and Northland in 2021 and on vaccine mandates and safety. In a minute issued on the Inquiry's website chair Grant Illingworth KC said that would include the effect on "social division and isolation, health and education, and business activity. Covid 19 response Inquiry chair Grant Illingworth KC. Photo: Screengrab / Covid 19 Inquiry "We will also hear from experts about the key decisions and their consequences, and lessons to be learned from what happened." The hearings would be in secure hearing rooms, with commissioners, witnesses, lawyers and media present. There was no provision for public attendance beyond those submitting but the live streams would run and be available as recordings as well, the minute said. Witnesses would be questioned by lawyers helping the inquiry, and commissioners could ask questions. A second public hearing was due next month in Wellington. That was to hear from key decisions makers who "led and informed" the government's response to the pandemic. This Royal Commission was set up under the previous Labour government, but its brief was expanded under the current government, with Illingworth taking the chairing role. A report from the first phase was delivered last year. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.